30
Mar

Amgen widened its lead among competing drugmakers in a promising new field of cardio treatments on the strength of late-stage results in which its in-development drug lowered LDL cholesterol by as much as 75%.

…read more

Source: Amgen’s PCSK9 drug slashes ‘bad’ cholesterol in PhIII, stoking blockbuster hopes

    

0 No comments